- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03845166
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Exelixis Clinical Trials
- Phone Number: 1-888-EXELIXIS (888-393-5494)
- Email: druginfo@exelixis.com
Study Contact Backup
- Name: Backup or International
- Phone Number: 650-837-7400
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- Exelixis Clinical Site #52
-
Liverpool, New South Wales, Australia, 2170
- Exelixis Clinical Site #53
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Exelixis Clinical #75
-
-
South Australia
-
Kurralta Park, South Australia, Australia, 5037
- Exelixis Clinical Site #56
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Exelixis Clinical Site #63
-
-
-
-
Antwerpen
-
Edegem, Antwerpen, Belgium, 2650
- Exelixis Clinical Site #44
-
-
Brussels
-
Bruxelles, Brussels, Belgium, 1200
- Exelixis Clinical Site #51
-
-
Oost-Vlaanderen
-
Gent, Oost-Vlaanderen, Belgium, 9000
- Exelixis Clinical Site #65
-
-
-
-
-
Brno, Czechia, 656 91
- Exelixis Clinical Site #21
-
Hradec Králové, Czechia, 500 05
- Exelixis Clinical Site #42
-
Olomouc, Czechia, 779 00
- Exelixis Clinical Site #10
-
Praha, Czechia, 140 59
- Exelixis Clinical Site #27
-
-
-
-
-
Bordeaux, France, 33076
- Exelixis Clinical #72
-
Caen Cedex 5, France, 14076
- Exelixis Clinical Site #32
-
Marseille, France, 13009
- Exelixis Clinical Site #48
-
Paris, France, 75015
- Exelixis Clinical Site #14
-
Pierre-Bénite, France, 69310
- Exelixis Clinical Site #39
-
Poitiers, France, 86000
- Exelixis Clinical Site #47
-
Suresnes, France, 92150
- Exelixis Clinical Site #22
-
Toulouse Cedex 9, France, 31059
- Exelixis Clinical Site #57
-
Villejuif, France, 94805
- Exelixis Clinical #77
-
-
Ferrand
-
Clermont, Ferrand, France, 63011
- Exelixis Clinical Site #46
-
-
Loire Atlantique
-
Saint-Herblain Cedex, Loire Atlantique, France, 44805
- Exelixis Clinical Site #37
-
-
-
-
-
Hamburg, Germany, 20249
- Exelixis Clinical Site #64
-
-
Baden-Wuerttemberg
-
Nürtingen, Baden-Wuerttemberg, Germany, 72622
- Exelixis Clinical Site #38
-
-
Bavaria
-
München, Bavaria, Germany, 81675
- Exelixis Clinical Site #28
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Germany, 48149
- Exelixis Clinical Site #31
-
-
-
-
-
Milan, Italy, 20141
- Exelixis Clinical Site #54
-
Napoli, Italy, 80131
- Exelixis Clinical #73
-
-
MI
-
Milano, MI, Italy, 20132
- Exelixis Clinical Site #67
-
-
PV
-
Pavia, PV, Italy, 27100
- Exelixis Clinical Site #69
-
-
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066 CX
- Exelixis Clinical Site #79
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1066CX
- Exelixis Clinical Site #82
-
-
South Holland
-
Rotterdam, South Holland, Netherlands, 3015 GD
- Exelixis Clinical #76
-
-
-
-
-
Barcelona, Spain, 08003
- Exelixis Clinical Site #18
-
Barcelona, Spain, 08023
- Exelixis Clinical Site #19
-
Barcelona, Spain, 08035
- Exelixis Clinical Site #29
-
Barcelona, Spain, 08036
- Exelixis Clinical Site #30
-
Madrid, Spain, 28007
- Exelixis Clinical Site #81
-
Madrid, Spain, 28040
- Exelixis Clinical Site #34
-
Madrid, Spain, 28041
- Exelixis Clinical Site #55
-
Madrid, Spain, 28046
- Exelixis Clinical Site #17
-
Sevilla, Spain, 41013
- Exelixis Clinical Site #16
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Exelixis Clinical Site #23
-
-
La Coruna
-
Santiago De Compostela, La Coruna, Spain, 15706
- Exelixis Clinical Site #20
-
-
-
-
England
-
London, England, United Kingdom, W1G6AD
- Exelixis Clinical #70
-
Sutton, England, United Kingdom, SM2 5PT
- Exelixis Clinical Site #40
-
-
Lancashire
-
Preston, Lancashire, United Kingdom, PR29HT
- Exelixis Clinical Site #68
-
-
-
-
California
-
Duarte, California, United States, 91010
- Exelixis Clinical Site #6
-
La Jolla, California, United States, 92093
- Exelixis Clinical Site #49
-
Los Angeles, California, United States, 90025
- Exelixis Clinical Site #7
-
Palo Alto, California, United States, 94304
- Exelixis Clinical #71
-
San Francisco, California, United States, 94158
- Exelixis Clinical Site #66
-
-
Florida
-
Lake Mary, Florida, United States, 32746
- Exelixis Clinical Site #15
-
Miami, Florida, United States, 33136
- Exelixis Clinical Site #24
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Exelixis Clinical Site #11
-
Atlanta, Georgia, United States, 30322
- Exelixis Clinical Site #80
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Exelixis Clinical Site #41
-
-
Kansas
-
Westwood, Kansas, United States, 66205
- Exelixis Clinical Site #36
-
-
Maine
-
Scarborough, Maine, United States, 04074
- Exelixis Clinical Site #62
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Exelixis Clinical Site #44
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Exelixis Clinical Site #4
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Exelixis Clinical Site #45
-
Grand Rapids, Michigan, United States, 49546
- Exelixis Clinical Site #2
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Exelixis Clinical Site #25
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Exelixis Clinical Site #13
-
-
New Jersey
-
East Brunswick, New Jersey, United States, 08816
- Exelixis Clinical Site #9
-
New Brunswick, New Jersey, United States, 08903
- Exelixis Clinical Site #83
-
-
New York
-
New York, New York, United States, 10029
- Exelixis Clinical Site #35
-
New York, New York, United States, 10065
- Exelixis Clinical #78
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Exelixis Clinical #74
-
Cleveland, Ohio, United States, 44106
- Exelixis Clinical Site #60
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Exelixis Clinical Site #59
-
Philadelphia, Pennsylvania, United States, 19107
- Exelixis Clinical Site #58
-
Pittsburgh, Pennsylvania, United States, 15232
- Exelixis Clinical Site #12
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Exelixis Clinical Site #61
-
Myrtle Beach, South Carolina, United States, 29572
- Exelixis Clinical Site #50
-
-
Tennessee
-
Germantown, Tennessee, United States, 37203
- Exelixis Clinical Site #33
-
-
Texas
-
Houston, Texas, United States, 77030
- Exelixis Clinical Site #3
-
San Antonio, Texas, United States, 78229
- Exelixis Clinical Site #1
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Exelixis Clinical Site #5
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Exelixis Clinical Site #8
-
Richmond, Virginia, United States, 23219
- Exelixis Clinical Site #43
-
-
Washington
-
Spokane, Washington, United States, 99208
- Exelixis Clinical Site #26
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cytologically or histologically confirmed solid tumor that is inoperable locally advanced, metastatic, or recurrent.
- Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor that is unresectable or metastatic and for which life-prolonging therapies do not exist or available therapies are intolerable or no longer effective.
- Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear cell histology (including those with a sarcomatoid component) who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
- Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with non-clear cell histology who have radiographically progressed following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
- Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor receptor 2 (HER-2) and who have radiographically progressed during or following treatment with at least one prior systemic anticancer regimen for inoperable locally advanced or metastatic disease.
- Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of the prostate). Neuroendocrine differentiation and other features permitted if adenocarcinoma is the primary histology.
Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type (confirmed via local testing report) and determined NOT to have microsatellite instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who received the following standard of care chemotherapy regimens as prior therapy for metastatic CRC:
- Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF monoclonal antibody (bevacizumab)
- Anti-EGFR monoclonal antibody (cetuximab or panitumumab)
- BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations
- Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1.
Tumor tissue material:
- Subjects in the non-biomarker cohort provide archival, if available, or fresh tumor tissue if it can be safely obtained.
- Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs), including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Adequate organ and marrow function.
- Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception.
- Female subjects of childbearing potential must not be pregnant at screening.
Exclusion Criteria:
- Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with regorafenib and/or TAS-102 (Cohort H only).
- Receipt of any type of small molecule kinase inhibitor within 2 weeks before first dose of study treatment.
- Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal anticancer therapy within 4 weeks before first dose of study treatment.
- Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
- Uncontrolled, significant intercurrent or recent illness.
- Concomitant use of certain medications.
- Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males and > 470 ms for females. Single ECGs are no longer permitted.
- Pregnant or lactating females.
- Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
- Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
- Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: XL092 Single-Agent Dose-Escalation Cohorts
Subjects will accrue in cohorts of 3-6 subjects in a standard "3 plus 3" design.
|
oral doses of XL092
|
Experimental: XL092 Single-Agent Expansion Cohorts
The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
|
oral doses of XL092
|
Experimental: XL092 + Atezolizumab Dose-Escalation Cohorts
Subjects will accrue in cohorts of 2-6 subjects in a "rolling 6" design.
|
oral doses of XL092
Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
Other Names:
|
Experimental: XL092 + Atezolizumab Expansion Cohorts
The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).
|
oral doses of XL092
Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
Other Names:
|
Experimental: XL092 + Avelumab Dose-Escalation Cohorts
Subjects will accrue in cohorts of 2-6 subjects in a "rolling 6" design.
|
oral doses of XL092
Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Escalation Stage: MTD/recommended dose for XL092
Time Frame: Up to 24 months
|
To determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with immune checkpoint inhibitors (ICIs) to subjects with advanced solid tumors
|
Up to 24 months
|
Cohort-Expansion Stage: Objective Response Rate (ORR)
Time Frame: Up to 24 months
|
To evaluate preliminary efficacy of XL092 when administered alone and in combination with ICIs by estimating ORR as assessed by the Investigator per RECIST 1.1
|
Up to 24 months
|
Cohort-Expansion Stage (except Cohort H): Progression-Free Survival (PFS)
Time Frame: Up to 24 months
|
To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with ICIs for specific cohorts by estimating the percentage of subjects with PFS at 6 months (PFS rate) per RECIST 1.1 as assessed by the Investigator
|
Up to 24 months
|
Cohort-Expansion Stage (Cohort H only): Overall Survival (OS)
Time Frame: Up to 24 months
|
To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with atezolizumab for subjects with RAS wild-type CRC (Cohort H Treatment Arms H-A and H-B) by estimating overall survival (OS)
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of Nonserious Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 36 months
|
To evaluate the safety of XL092 when administered alone and in combination with ICIs through the evaluation of incidence and severity of nonserious AEs and SAEs, including immune-related adverse events (irAEs), and adverse events of special interest (AESIs)
|
Up to 36 months
|
Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)
Time Frame: Up to 24 months
|
To evaluate the Tmax of XL092 alone and in combination with ICI
|
Up to 24 months
|
Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)
Time Frame: Up to 24 months
|
To evaluate the Cmax of XL092 alone and in combination with ICI
|
Up to 24 months
|
Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)
Time Frame: Up to 24 months
|
To evaluate the AUC 0-24 of XL092 alone and in combination with ICI
|
Up to 24 months
|
Dose-Escalation Stage: Terminal Half-Life
Time Frame: Up to 24 months
|
To evaluate the terminal half-life of XL092 alone and in combination with ICI
|
Up to 24 months
|
Dose-Escalation Stage: Apparent Clearance (CL/F)
Time Frame: Up to 24 months
|
To evaluate the CL/F of XL092 alone and in combination with ICI
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Neoplasms
- Carcinoma, Renal Cell
- Breast Neoplasms
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Avelumab
- Atezolizumab
Other Study ID Numbers
- XL092-001
- 2020-003569-21 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on XL092
-
ExelixisRecruitingHead and Neck Squamous Cell CarcinomaUnited States
-
ExelixisArcus Biosciences, Inc.RecruitingAdvanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsUnited States
-
ExelixisRecruitingColorectal CancerUnited States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
-
ExelixisRecruitingRenal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate CancerUnited States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
-
ExelixisRecruitingNon-Clear Cell Renal Cell CarcinomaUnited States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
-
Chong Kun Dang PharmaceuticalRecruitingCOVID-19 PneumoniaKorea, Republic of
-
Hoffmann-La RocheRecruitingCarcinoma, Non-Small-Cell LungKorea, Republic of, France, Spain, Taiwan, United States, Israel, Australia, United Kingdom